School of Medicine
Showing 1-94 of 94 Results
-
Ranjana Advani
Saul A. Rosenberg, MD, Professor of Lymphoma
On Leave from 12/25/2025 To 01/25/2026Current Research and Scholarly InterestsClinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.
The research program is highly collaborative with radiation oncology, industry, pathology and dermatology. -
Ash A. Alizadeh, MD/PhD
Moghadam Family Professor
Current Research and Scholarly InterestsMy research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.
Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials. -
Danielle Francoise Atibalentja, MD, PhD
Instructor, Medicine - Oncology
BioDanielle F Atibalentja received her PhD in Immunology at Washington University in St Louis and her MD at UCSF School of medicine. She trained in Internal medicine at Washington University/Barnes-Jewish Hospital in St Louis and recently completed Hematology/Oncology Fellowship at Stanford. Her primary clinical interest is in treating patients with B-cell lymphomas. Her long-term research goals are to better understand B-cell responses in the setting of malignancy to develop immune-based therapies for cancer treatment. She currently studies how the MYC oncogene shapes B-cell and antibody responses during T-cell lymphomagenesis.
-
Allison Betof, MD, PhD
Associate Professor of Medicine (Oncology)
BioDr. Allison Betof is an Associate Professor of Medicine (Oncology), Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford University School of Medicine. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof’s laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), Melanoma Research Alliance, and Melanoma Research Foundation.
-
Douglas W. Blayney
Professor of Medicine (Oncology), Emeritus
Current Research and Scholarly InterestsImproving the quality of cancer care at Stanford, in our network of care, and nationally
-
Nam Quoc Bui
Clinical Associate Professor, Medicine - Oncology
BioDr. Bui is a Clinical Associate Professor of Medicine at the Stanford Cancer Institute and a specialist in Sarcoma. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data.
He is involved in numerous sarcoma clinical trials, leading efforts to take new therapeutics from the lab to clinical practice. His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies. He also is involved in education at the Stanford University School of Medicine, serving as a lecturer and mentor to medical students, residents, and oncology fellows. Dr. Bui is the founding Editor-in-Chief of the journal “Current Problems in Cancer: Case Reports”, an international, peer-reviewed journal that publishes groundbreaking cases that give insight into redefining concepts in cancer. He also serves as the Chair of the Data Safety Monitoring Committee at the Stanford Cancer Institute, overseeing the board that reviews all investigator-initiated cancer trials run at Stanford. -
Robert W. Carlson
Professor of Medicine (Oncology and General Internal Medicine/Medical Informatics) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsClinical investigations in breast cancer include institutional and NSABP studies of chemoprevention, adjuvant therapy, psychosocial interventions, treatment of metastatic disease, methods of decreasing anthracycline cardiotoxicity, and modulation of multidrug resistance. Research in meta-analysis includes the performance of meta-analysis in a wide variety of settings in cancer treatment by the international Meta-Analysis Group in Cancer.
-
Jennifer Caswell-Jin
Assistant Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research is on the translational application of next-generation sequencing technologies to breast cancer care: (1) the value of hereditary cancer genetic panel testing in clinical practice, (2) the mechanisms by which inherited genetic variants lead to breast cancer development, and (3) the analysis of somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.
-
Amina Chaudhry, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Amina Chaudhry is a medical oncologist in the Division of Oncology at Stanford University School of Medicine. As part of Stanford University’s Breast Cancer Program, she specializes in treating patients diagnosed with breast cancer.
Dr. Chaudhry completed a residency in internal medicine at the University of Tennessee Health Science Center. She gained advanced training in hematology and oncology through a fellowship at University of Illinois Chicago. She is certified by the American Board of Internal Medicine.
Dr. Chaudhry’s research focuses on improving outcomes in disadvantaged populations with breast cancer. In 2022, she received the Repurposing Research to Address Diversity, Equity, and Inclusion grant to support underrepresented patients with early-stage breast cancer.
Dr. Chaudhry has published research in journals including Annals of Oncology, Journal of Clinical Oncology, and Blood Advances. She has presented her work at the annual meetings of the American Society of Clinical Oncology (ASCO), San Antonio Breast Cancer Symposium (SABCS), and American Society of Hematology (ASH).
Dr. Chaudhry has a strong interest in tackling healthcare inequities and improving access to clinical trials. -
Christopher T Chen, MD
Assistant Professor of Medicine (Oncology)
BioDr. Chen is board-certified, fellowship-trained physician in oncology and hematology. He is also an Assistant Professor in the Division of Oncology in the Department of Medicine at Stanford University School of Medicine.
Dr. Chen attended Harvard College, where he graduated summa cum laude and Phi Beta Kappa in molecular biology. He went to medical school at Washington University in St. Louis on a full-tuition merit scholarship, graduating with Alpha Omega Alpha honors, and did his residency training in internal medicine at Massachusetts General Hospital and hematology/oncology fellowship in the Harvard Dana-Farber Cancer Institute/Massachusetts General Hospital program.
Dr. Chen is a member of the American Society of Clinical Oncology, European Society for Medical Oncology, and American Association for Cancer Research. -
Curtis R. Chong, MD, PhD, MPhil, FACP
Clinical Assistant Professor, Medicine - Oncology
BioDr. Chong was recruited to Stanford from the Memorial Sloan Kettering (MSK) Cancer Center, where he led MSK's launch of the early drug development and immunotherapy clinical trials program in New Jersey. At MSK, Dr. Chong was a member of the gastrointestinal oncology service and was one of two MSK physicians in New Jersey who specialized in treating melanoma. Prior to joining MSK, Dr. Chong was a member of the thoracic oncology service at the Dana-Farber Cancer Institute and an attending physician at the Massachusetts General Hospital and Brigham and Women's Hospital, all ailiates of Harvard Medical School.
Dr. Chong completed his categorical residency in internal medicine at the Massachusetts General Hospital/Harvard Medical School, his oncology fellowship at the Dana-Farber Cancer Institute, and is board-certified in internal medicine and medical oncology. He has received research support from the American Society of Clinical Oncology (Young Investigator Award), Uniting Against Lung Cancer, and the American Cancer Society. Dr. Chong has been published in the New England Journal of Medicine, Nature, Nature Medicine, Nature Chemical Biology, JAMA Oncology, and his research on drug discovery has been featured in the New York Times and Popular Science.
Born and raised in Honolulu where he attended public schools, Dr. Chong sang in the Honolulu Boy Choir, and was the 1993 Honolulu Star Bulletin Newspaper Boy of the Year. He received his A.B. in biochemical sciences from Harvard University magna cum laude followed by an M.Phil. in Chemistry with Sir Alan Fersht at the University of Cambridge (Emmanuel College). He then received his MD and PhD in pharmacology from The Johns Hopkins University School of Medicine.
An intrepid traveler and avid long-distance runner, Dr. Chong has visited 54 countries and completed 126 marathons in all 50 states, 18 countries, and 6 on continents. -
Gilbert Chu
Professor of Medicine (Oncology) and of Biochemistry
Current Research and Scholarly InterestsAfter shuttering the wet lab, we have focused on: a point-of-care device to measure blood ammonia and prevent brain damage; a human protein complex that juxtaposes and joins DNA ends for repair and V(D)J recombination; and strategies for teaching students and for reducing selection bias in educational programs.
-
Michael F. Clarke, M.D.
Karel H. and Avice N. Beekhuis Professor of Cancer Biology
Current Research and Scholarly InterestsDr. Clarke maintains a laboratory focused on two areas of research: i) the control of self-renewal of normal stem cells and diseases such as cancer and hereditary diseases; and ii) the identification and characterization of cancer stem cells. His laboratory is investigating how perturbations of stem cell regulatory machinery contributes to human disease. In particular, the laboratory is investigating epigenetic regulators of self renewal, the process by which stem cells regenerate themselves.
-
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
On Partial Leave from 10/01/2025 To 04/15/2026Current Research and Scholarly InterestsMulti- modality treatment of Head and Neck Cancer
Phase 1 clinical trials -
Steven M. Corsello
Assistant Professor of Medicine (Oncology) and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsOur laboratory operates at the intersection of functional genomics and chemical biology, with the goal of advancing novel molecular mechanisms of cancer inhibition to clinical use. We aim to 1) leverage phenotypic screening and functional genomics to determine novel anti-cancer mechanisms of small molecules, 2) develop new targeted therapy approaches against solid tumors, and 3) build a comprehensive community resource for drug repurposing discovery.
-
Christina Curtis
RZ Cao Professor and Professor of Genetics
Current Research and Scholarly InterestsThe Curtis laboratory for Cancer Computational and Systems Biology is focused on the development and application of innovative experimental, computational, and analytical approaches to improve the diagnosis, treatment, and early detection of cancer.
-
Millie Das
Clinical Professor, Medicine - Oncology
BioDr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and is an active member of the VA national Lung Cancer Working Group and Lung Cancer Precision Oncology Program. In 2023, she was elected President the Association of Northern California Oncologists (ANCO), where she displays her passion for patient advocacy and also for clinician education by helping to organize Bay Area focused continuing medical education programs. She is the VA site director for the Stanford fellowship program and leads the VA thoracic tumor board on a biweekly basis. She has a strong interest in clinical research, serving as a principal investigator for multiple clinical and translational studies at the Palo Alto VA, and also as a co-investigator on all of the lung cancer trials at Stanford. In her free time, she enjoys spending time with her family, traveling, and running.
-
James C. Dickerson, MD MS
Clinical Assistant Professor, Medicine - Oncology
BioDr. Dickerson is a medical oncologist in the Division of Medical Oncology at Stanford University School of Medicine, specializing in the care of patients with breast cancer. In addition to seeing patients in the clinic, he researches how health policy, data science, and emerging technologies can improve cancer care delivery. His research group focuses on three core objectives: (1) developing financially sustainable cancer care programs, (2) analyzing large clinical and administrative datasets to identify gaps where policy can improve equity and outcomes, and (3) conducting clinical and implementation research to determine the most effective ways to deliver high-quality, evidence-based oncology care.
Across these objectives, Dr. Dickerson integrates traditional real-world data analytics with modern natural language processing approaches, including large language models, to study cancer care delivery. His group develops and applies LLM-based tools to improve the extraction, structuring, and interpretation of complex clinical information from electronic health records, to enhance clinical decision-making, care coordination, and health policy evaluation.
Dr. Dickerson received his undergraduate degree from Vanderbilt University and graduated magna cum laude from the University of Mississippi Medical Center. He completed his internship and residency in Internal Medicine at Stanford University, followed by fellowship training in Hematology and Oncology. During his fellowship, Dr. Dickerson earned a Master’s degree in Health Policy and completed post-doctoral research in the Department of Health Policy. -
Milana V. Dolezal, MD, MSci
Clinical Associate Professor, Medicine - Oncology
BioDr. Dolezal is a board-certified hematologist-oncologist with Stanford Medicine Cancer Center in Emeryville and a clinical associate professor in the Stanford School of Medicine, Division of Oncology.
She strives to work with patients to develop care plans that are comprehensive and personalized achieve the best possible outcomes and quality of life.
Dr. Dolezal also has extensive experience in research and drug development. She previously held positions as a clinical scientist, assistant medical director, and associate medical director in the BioOncology Therapeutics unit of the biotechnology company Genentech.
She has conducted clinical research into fertility preservation in patients with breast cancer, advanced treatments for triple-negative breast cancer, and patients’ adherence to anti-cancer therapy. She has co-authored articles on her research findings that appeared in the Journal of Clinical Oncology, Cancer, and other peer-reviewed publications.
She also co-authored the chapter “Progression from Hormone-Dependent to Hormone-Independent Breast Cancer” in the textbook Hormones, Genes and Cancer published by Oxford University Press.
Dr. Dolezal has made presentations to her peers at meetings of the American Association for Cancer Research, American Society of Clinical Oncology, and European Cancer Organisation. -
Alice C. Fan
Associate Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsDr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.
-
Dean W. Felsher
Professor of Medicine (Oncology) and of Pathology
Current Research and Scholarly InterestsMy laboratory studies the molecular basis of cancer with a focus on understanding when cancer can be reversed through targeted oncogene inactivation.
-
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine, Emeritus
Current Research and Scholarly InterestsClinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.
-
James Ford
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsMammalian DNA repair and DNA damage inducible responses; p53 tumor suppressor gene; transcription in nucleotide excision repair and mutagenesis; genetic determinants of cancer cell sensitivity to DNA damage; genetics of inherited cancer susceptibility syndromes and human GI malignancies; clinical cancer genetics of BRCA1 and BRCA2 breast cancer and mismatch repair deficient colon cancer.
-
Kristen N Ganjoo
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsGiant cell tumor of the bone
Gastrointestinal stromal tumors
Soft tissue sarcoma
Osteosarcoma -
Neel K. Gupta
Clinical Associate Professor, Medicine - Oncology
Current Research and Scholarly InterestsI have specific interest in the pathobiology and management of individuals with AIDS-related and primary central nervous system lymphomas.
-
Gregory M. Heestand, MD
Clinical Associate Professor, Medicine - Oncology
BioDr. Heestand is a board-certified medical oncologist with a focus on gastrointestinal cancers, primarily hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. He serves as the medical oncology champion of the Stanford Hepatobiliary Tumor Board, as well as the principal investigator of multiple clinical trials. He collaborates with campus laboratories to help develop new biomarker and treatment technologies. He is the former director of the Stanford Oncology Fellowship Program.
Dr. Heestand and his team take great pride in helping patients and their families face gastrointestinal cancer.
Outside of the clinic, Dr. Heestand enjoys playing the piano, teaching his kids about music, cooking for friends and family, and surfing the internet for interesting things to read. -
Thomas Holden, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Holden is a board-certified, fellowship-trained medical oncologist. He is a Clinical Assistant Professor at Stanford University School of Medicine.
He specializes in care for people with gastrointestinal cancer including those of the colon, rectum, esophagus, liver, pancreas, and stomach. Dr. Holden works closely with patients to prepare personalized, comprehensive, and compassionate care plans that optimize healing and quality of life.
Dr. Holden has conducted research into a wide range of subjects. He co-developed and established a multi-center trial investigating a new treatment regimen for gastric cancer. He has studied use of a fitness tracker to assess activity levels and toxicities in patients with colorectal cancer. He also has written invited commentary on the rapidly advancing field of genetic testing as well as a review on recent updates on the treatment of early-stage rectal cancer.
He has published his research findings in articles in peer-reviewed journals including JAMA, the Journal of Clinical Oncology, Cortex, and elsewhere. He has made poster presentations to his peers at meetings including the ASCO Gastrointestinal Cancers symposium and House Staff Quality Improvement and Patient Safety Conference, a meeting held annually at Thomas Jefferson University.
Dr. Holden has volunteered his time and expertise to help improve access to health care for homeless and underserved populations.
In his free time, he runs, reads, plays the acoustic guitar, and travels. -
Sandra Horning
Professor of Medicine, Emerita
Current Research and Scholarly InterestsClinical Interests: Hodgkin's disease and non-Hodgkin's lymphoma. Research Interests: clinical trials in Hodgkin's disease and malignant lymphoma including high dose therapy and autografting, complications of cytotoxic therapy, novel therapeutics, and clinicopathologic correlations.
-
Robert Hsieh
Adjunct Clinical Assistant Professor, Medicine - Oncology
BioRobert W. Hsieh, M.D. Ph.D. is a medical oncologist who specializes in the treatment of prostate cancer, bladder cancer, kidney (renal) cancer and testicular cancer as a member of Stanford's multi-disciplinary Urologic Cancer Program. Dr. Hsieh obtained his M.D. and Ph.D. degrees at the University of Chicago (Pritzker School of Medicine) and subsequently came to Stanford to complete his Internal Medicine residency and Hematology and Oncology fellowship training (with a clinical focus on genitourinary cancers).
Dr. Hsieh has also had extensive experience in basic lab research (cancer stem cells, target identification and validation, pre-clinical drug discovery) having done post-doctoral work in the Clarke Lab in the Institute for Stem Cell Biology and Regenerative Medicine. He is currently involved in early phase clinical trials in immuno-oncology in industry. -
Haruka Itakura, MD, PhD
Assistant Professor of Medicine (Oncology)
BioDr. Haruka Itakura is an Assistant Professor of Medicine (Oncology) in the Stanford University School of Medicine, a data scientist, and a practicing breast medical oncologist at the Stanford Women’s Cancer Center. She is board-certified in Oncology, Clinical Informatics, Hematology, and Internal Medicine. Her research mission is to drive medical advances at the intersection of cancer and data science, applying state-of-the-art machine learning/artificial intelligence techniques to extract clinically actionable knowledge from heterogeneous multi-scale cancer data to improve patient outcomes. Her ongoing research to develop robust methodologies and apply cutting-edge techniques to analyze complex cancer big data was catapulted by an NIH K01 Career Development Award in Biomedical Big Data Science after obtaining a PhD in Biomedical Informatics at Stanford University. Her cancer research focuses on extracting radiomic (pixel-level quantitative imaging) features of tumors from medical imaging studies and applying machine learning frameworks, including radiogenomic approaches, for the integrative analysis of heterogeneous, multi-omic (e.g., radiomic, genomic, transcriptomic) data to accelerate discoveries in cancer diagnostics and therapeutics. Her current projects include prediction modeling of survival, treatment response, recurrence, and CNS metastasis in different cancer subtypes; detection of occult invasive breast cancer; and identification of novel therapeutic targets. Her ultimate goal is to be able to translate her research findings back to the clinical setting for the benefit of patients with difficult-to-treat cancers.
-
Charlotte D. Jacobs M.D.
Drs. Ben and A. Jess Shenson Professor in the School of Medicine, Emerita
Current Research and Scholarly InterestsClinical Interests: general oncology, sarcomas. Research Interests: clinical trials in solid tumors.
-
Hanlee P. Ji
Professor of Medicine (Oncology) and, by courtesy of Electrical Engineering
Current Research and Scholarly InterestsCancer genomics and genetics, translational applications of next generation sequencing technologies, development of molecular signatures as prognostic and predictive biomarkers in oncology, primary genomic and proteomic technology development, cancer rearrangements, genome sequencing, big data analysis
-
Esther M. John
Professor (Research) of Epidemiology and Population Health and of Medicine (Oncology)
Current Research and Scholarly InterestsDr. John has extensive expertise in conducting population-based epidemiologic studies and has led as Principal Investigator multiple large-scale studies, including multi-center studies with a study site in the San Francisco Bay Area with its diverse population. Many of her studies and collaborations investigated cancer health disparities. Her research has focused on the role of modifiable lifestyle factors (e.g., body size, physical activity, diet), hormonal factors, early-life exposures, genetic variants, and gene-environment interactions; differences in risk factors by race and ethnicity, breast cancer subtypes, and prostate cancer subtypes; risk factors for familial breast cancer and second primary breast cancer, as well as prognostic factors related to survival disparities.
As Principal Investigator, Dr. John has led a number of studies conducted in the San Francisco Bay Area, including:
- the Northern California site of the Breast Cancer Family Registry, an on-going prospective multi-generational cohort of over 13,000 families established in 1995 at six international sites;
- the San Francisco Bay Area Breast Cancer Study, a population-based case-control study in nearly 5,000 African American, Hispanic, and non-Hispanic White women that investigated the role of modifiable lifestyle factors and other risk factors;
- the California site of the Breast Cancer Health Disparities Study that investigated genetic variability and breast cancer risk and survival in Hispanic and non-Hispanic White populations in the context of genetic admixture;
- the Breast Cancer Etiology in Minorities (BEM) Study, a pooled analysis of risk factors for breast cancer subtypes in minoritized racial and ethnic populations;
- the Northern California site of the WECARE Study that investigates risk factors for second primary contralateral breast cancer;
- the Second Primary Breast Cancer Disparities Study, a pooled analysis of risk factors for contralateral and ipsilateral second primary breast cancer in a diverse population;
- the San Francisco Bay Area Prostate Cancer Study, a population-based case-control study of lifestyle and genetic risk factors for advanced and localized disease.
These studies collected and pooled extensive data and biospecimens and continue to support numerous ancillary studies, collaborations and international consortia and have contributed to a better understanding of cancer risk and survival in minoritized racial and ethnic populations.
Dr. John is a founding PI of the LEGACY Girls Study, a prospective cohort established in 2011 that investigates early life exposures in relation to pubertal development outcomes, breast tissue characteristics, and behavioral and psychosocial outcomes in the context of having a family history or breast cancer.
In 2023, Dr. John joined the Stanford investigator team of the MOSAAIC (The Multiethnic Observational Study in American Asian and Pacific Islander Communities) Study, a five-center study to improve health of American Asian, Native Hawaiian, and Pacific Islander populations. -
Tyler Johnson
Clinical Associate Professor, Medicine - Oncology
BioDr. Tyler Johnson--a clinical associate professor of medicine and oncology at Stanford University Medical School--is a physician, author, educator, and humanitarian. A medical oncologist, Dr. Johnson sees patients with all types of gastrointestinal malignancies and particularly focuses on patients with neuroendocrine tumors, colon cancer, and pancreas cancer.
Dr. Johnson served for many years as a leader of the Stanford Hospital in-patient oncology services and helped launch the hospital's first direct care inpatient service, med 12. He is also responsible for helping respond to the surge of patients that came with the pandemic and its aftermath.
Dr. Johnson views the practice of medicine largely as an educational endeavor. He directs the Stanford University Hematology/Oncology Fellowship Program and spends significant time teaching trainees at levels. To that end, for many years he has taught medical students, residents, and fellows—including hosting them as temporary and longer-term apprentices in his oncology clinic and working with them on the inpatient housestaff oncology service. He emphasizes diversity and inclusion in his mentoring efforts and has worked to promote the professional development of medical trainees across the training spectrum--from undergraduates to oncology fellows.
The winner of multiple Stanford Medicine teaching awards, Dr. Johnson has established himself as a regional and increasingly as a national leader and innovator in the education of oncology fellows, including by developing novel teaching methods that have been presented across the country, including at national meetings. He also works as one of the principal faculty members of the Stanford Educators-4-CARE program.
Dr. Johnson and his co-host, Henry Bair, became concerned about the loss of a shared sense of meaning in the medical profession and, together, have taught multiple classes in the Medical School and, in the spring of 2022, founded The Doctor's Art podcast. Since then, the podcast has become one of the most listened to medical podcasts in the world and has won multiple national awards, making it one of the most lauded and most popular medical podcasts.
Finally, Dr. Johnson is an author with a growing reputation for insightful analysis of the intersection of medicine, ethics, and spirituality. His writings has been featured by Religion News Service, the Salt Lake Tribune, BYU Studies, Dialogue, and The San Jose Mercury News, where he is a regular contributor. He serves on the editorial boards of both BYU Studies and Wayfare and has written extensively on modernity loss of faith and meaning and the role of spirituality in constructing a purposeful and fulfilling life. -
Hyunseok Kang
Clinical Instructor, Medicine - Oncology
Current Research and Scholarly InterestsMy research interest lies in development of precision oncology based approaches and novel therapeutics for rare cancers of head and neck, including adenoid cystic cancers, salivary duct cancers, sinonasal cancers and thyroid cancers.
-
Ali Raza Khaki, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Khaki is a medical oncologist and clinical assistant professor at Stanford University School of Medicine.
In his clinical practice, he treats patients with all forms of genitourinary cancer, including kidney, bladder, prostate, and testicular. He also regularly attends on the inpatient oncology service at Stanford Hospital.
With each patient, he is devoted to providing exceptional, humanistic care and has been recognized throughout his career for his humanism. As a medical student, he was named to the national Gold Humanism Honor Society and he received the Reza Gandjei Humanism Award as a medical resident at UCSF.
His research interests include novel therapies for genitourinary cancers, with a focus on urothelial cancer outcomes. He is the site principal investigator for multiple clinical trails investigating new therapies for genitourinary cancers.
Dr. Khaki is also active working clinically in inpatient oncology and is a Unit Based Medical Director for G1, an oncology hospital unit and is the Director of Inpatient Oncology. In this role, he oversees the inpatient oncology teams, works closely with the cancer center to develop new transitions of care pathways from inpatient to outpatient and has co-led an inpatient oncology research group to study quality improvement, care delivery and end-of-life care for patients with cancer.
Dr. Khaki has earned honors and recognition from the American Association for Cancer Research, American Society of Clinical Oncology, Bladder Cancer Advocacy Network, Conquer Cancer Foundation, and other organizations.
He has authored numerous articles on topics such as immunotherapy for urothelial cancer, management of cancer patients with COVID-19, and utilization of end-of-life care by cancer patients. In addition, he is an editor for HemOnc.org and theMednet, a physician-only online community where members share clinical questions and answers. -
Saad A. Khan, MD
Associate Professor of Medicine (Oncology)
BioDr. Khan is a fellowship-trained cancer specialist with board certification in oncology and hematology. He is an assistant professor in the Department of Medicine, Division of Oncology.
Dr. Khan focuses on the treatment of head and neck cancers, advanced thyroid cancers, and neuroendocrine tumors. He recognizes the broad effects of these conditions on daily living and aims to develop personalized, comprehensive treatment plans that optimize health and quality of life.
Dr. Khan’s research interests include therapeutic clinical trials as well as ways to reduce toxicities that some patients may experience when receiving cancer treatment. His research activities include ongoing clinical trials of targeted and immune therapy for aggressive thyroid cancer.
He has published numerous articles on his research discoveries in peer-reviewed journals such as the JAMA Oncology, Investigational New Drugs, and others. Topics include new drug treatments for small cell lung cancer and for cancers of the head and neck, racial and gender disparities in certain types of cancer, and management of the potentially toxic effects of cancer therapies.
Dr. Khan is a member of the NRG Head and Neck Committee. NRG brings together internationally recognized groups (the first words in their names form the acronym “NRG”) to conduct cancer clinical research and share study results. The objective is to inform clinical decision making and healthcare policy worldwide.
Dr. Khan is a member of the ECOG Head and Neck Core and Thoracic Committees. ECOG (Eastern Cooperative Oncology Group) is part of one of the five groups of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) Program.
He also is a member of the National Cancer Institute’s Central IRB for Early Phase Clinical Trials.
When not providing patient care or conducting research, Dr. Khan enjoys spending time with his family, hiking, and relaxing at the beach. -
Youn H Kim, MD
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Current Research and Scholarly InterestsClinical research in cutaneous lymphomas, especially, mycosis fungoides; studies of prognostic factors, long-term survival results, and effects of therapies. Collaborative research with Departments of Pathology and Oncology in basic mechanisms of cutaneous lymphomas. Clinical trials of new investigative therapies for various dermatologic conditions or clinical trials of known therapies for new indications.
-
Allison W. Kurian, M.D., M.Sc.
Professor of Medicine (Oncology) and of Epidemiology and Population Health
Current Research and Scholarly InterestsI aim to understand cancer burden and improve treatment quality at the population level. I have a strong focus on genetic risk assessment and precision oncology. I lead epidemiologic studies of cancer risk factors, clinical trials of novel approaches to cancer risk reduction, and decision analyses of strategies to optimize cancer outcomes.
-
David Kurtz
Assistant Professor of Medicine (Oncology)
On Partial Leave from 01/02/2026 To 04/30/2026Current Research and Scholarly InterestsImplementation of noninvasive detection of malignancies in the clinic remains difficult due to both technical and clinical challenges. These include necessary improvements in sensitivity and specificity of biomarkers, as well as demonstration of clinical utility of these assays. My research focuses on technical development and implementation of assays to detect and track cancers in order to facilitate personalized disease management.
-
Ronald Levy, MD
Robert K. and Helen K. Summy Professor in the School of Medicine
Current Research and Scholarly InterestsClinical Interests: lymphoma. Research Interests: Immunology and molecular biology of lymphoid malignancy; molecular vaccines for cancer.
-
Michael Lim, M.D.
Stanford Medicine Endowed Chair of the Department of Neurosurgery, Professor of Neurosurgery and, by courtesy, of Radiation Oncology, of Medicine, of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology and Neurological Sciences
BioDr. Lim is the Chair of the Department of Neurosurgery and a board-certified neurosurgeon specializing in brain tumors and trigeminal neuralgia.
Dr. Lim’s clinical interests include the treatment of benign and malignant brain tumors, with special interest in gliomas, meningiomas, metastatic tumors, and skull base tumors. Dr. Lim also specializes in surgical treatments for trigeminal neuralgia. During his time at Johns Hopkins, Dr. Lim built one of the largest brain tumor and trigeminal neuralgia practices and utilized the most advanced surgical technologies and techniques for his patients. As a passionate voice for patient experience, he has been recognized by his peers and patients for his integrity and compassionate care, including a Service Excellence Award from HealthNetwork Foundation.
As a mentor, he has garnered numerous teaching awards, including being honored as an outstanding teacher by Johns Hopkins University School of Medicine. He is actively involved in shaping education for neurosurgery and oncology across the United States and around the world. He is the recipient of the prestigious 2023 Abhijit Guha Award in Neuro-Oncology.
Dr. Lim’s research interests focus on harnessing the immune system to fight cancer. His laboratory focuses on understanding mechanisms of immune evasion by cancer cells. He has successfully translated his findings from the laboratory to the clinics and has conducted and led several large national immunotherapy clinical trials for brain tumors.
Dr. Lim’s bibliography contains well over 300 articles on topics such as immunotherapy for glioblastoma, long-term survival of glioma patients treated with stereotactic radiation, and treatment of neuropathic pain. His work has appeared in Science Translational Medicine, Clinical Cancer Research, Lancet Oncology, Nature Immunology, and many more publications. He also has written 20 book chapters and monographs.
Dr. Lim is a world leader in immunotherapy for brain tumors. In addition to being invited world-wide to give lectures and seminars, he has given platform presentations on the topics of immunotherapy for brain tumors, neurosurgical techniques and management of brain tumors at the American Society of Clinical Oncologists, American Academy of Neurological Surgeons, Radiological Society of North America, Annual Symposium on Brain and Spine Metastases, Congress of Neurological Surgeons, and other meetings. In addition, he has served as platform chairman of the CNS session at the American Society for Clinical Oncology conference.
Dr. Lim is a member of the American Society for Clinical Oncology, Congress of Neurological Surgeons, American Association of Neurological Surgeons, and Society for Neuro-Oncology. Dr. Lim served as the program co-chair of the Society for Neuro-Oncology and CNS section of the American Society for Clinical Oncology. He also served on many executive committees, including the Executive Committee for the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.
Trigeminal neuralgia treatment: https://www.youtube.com/watch?v=-n8nvwkwZik
Trigeminal neuralgia patient stories: https://www.youtube.com/watch?v=kClePRPYlQs&t=1s -
Janice Lu
Clinical Professor, Medicine - Oncology
BioDr. Janice Lu is Clinical Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine. She specializes in the treatment of breast cancer, with expertise in hormone receptor–positive and HER2-positive disease, antibody-drug conjugates, and immunotherapy. Dr. Lu has led and contributed to multiple clinical trials, including playing a key role in the EMERALD trial, which resulted in FDA approval of the first oral SERD for ESR1-mutated ER+/HER2- metastatic breast cancer. Her translational research focuses on liquid biopsy, epigenetics, AI and multiomics approaches to treatment resistance. She has chaired national sessions on precision oncology and holds leadership roles with NRG Oncology and ASCO, including Vice-Chair of the NRG Immunotherapy Subcommittee and Track Leader for ASCO’s Developmental Therapeutics and Targeted Therapy Education Program. She has also served on committees for the National Comprehensive Cancer Network (NCCN) and the Southwest Oncology Group (SWOG).
Dr. Lu completed her Hematology and Oncology fellowship at New York University School of Medicine and earned a PhD in epigenetics under the mentorship of late Dr. David Allis, a pioneer in the field and 2018 Lasker Laureate. Prior to joining Stanford, she was Director of Breast Medical Oncology and led the Circulating Tumor Cell (CTC) Core Lab at Northwestern University Feinberg School of Medicine, before returning to the Bay Area to be with her family and to further expand research and patient-centered care. -
Arnav Mehta, MD, PhD
Adjunct Clinical Assistant Professor, Medicine - Oncology
BioDr. Mehta is a board-certified, fellowship-trained medical oncologist at the Stanford Medicine Cancer Center. He is also an adjunct clinical assistant professor in the gastrointestinal (GI) oncology group of the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Mehta specializes in gastrointestinal cancer, with a particular focus on pancreatic and gastric cancers. He also treats colorectal cancers. His treatment specialties include immunotherapy — helping a patient’s immune system fight cancer — and targeted therapies, which send cancer-fighting drugs to specific cancer cell molecules.
His research interests include understanding why GI cancers resist treatments and identifying new ways to treat these tumors. In particular, he is interested in GI tumor immunology, which focuses on directing a person’s immune system to help destroy cancer cells. He also has a special interest in tumor plasticity, which represents the ability of a tumor cell to evolve and develop resistance to therapies.
Dr. Mehta has earned research awards and grants from organizations including the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), and the National Institutes of Health.
Dr. Mehta has published in many peer-reviewed journals, including Nature, Nature Genetics, Nature Immunology, Nature Medicine, Nature Cancer, Cancer Discovery and Immunity. He has written book chapters on subjects including esophageal and gastric cancer. He has also presented his research on topics including tumor immunology and pancreatic cancer at dozens of symposia and meetings around the country.
Dr. Mehta is a member of the AACR and ASCO. -
Beverly S. Mitchell, M.D.
George E. Becker Professor of Medicine, Emerita
Current Research and Scholarly InterestsBeverly Mitchell's research relates to the development of new therapies for hematologic malignancies, including leukemias and myelodsyplastic syndromes. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. She is also interested in the translation of these studies into clinical trials.
-
Joel Neal, MD, PhD
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsI am a thoracic oncologist who cares for patients with non-small cell lung cancer, malignant mesothelioma, and other thoracic malignancies. I design and conduct clinical trials of novel therapies in collaboration with other researchers and pharmaceutical companies. These generally focus on two areas, 1) targeted therapies against particular mutations in cancers (for example EGFR, ALK, ROS1, HER2, KRAS, MET, and others) and 2) the emerging field of immunotherapy in cancer, using anti PD-1/PD-L1 therapies in combination with other agents, and also developing cellular therapies. I also collaborate with other researchers on campus to apply emerging technologies to cancer therapy, for example, circulating tumor DNA detection. Additionally, in my role as the Cancer Center IT Medical Director, I coordinate projects relating to our use of the electronic health record to improve provider efficiency and facilitate patient care.
-
Dale Gene O'Brien
Adjunct Clinical Assistant Professor, Medicine - Oncology
BioDale O’Brien, MD, MPH is adjunct faculty at the Stanford University School of Medicine in the Oncology Division. He founded several medical clinics for vulnerable populations in under-resourced areas of northern California where he has been a practicing physician for more than four decades.
A graduate of the University of Missouri School of Medicine, he took postgraduate training at the Oregon Health & Science University, and the University of California (San Francisco) / University of California School of Public Health. He is board certified by the American Board of Family Medicine and by the American Board of Preventive Medicine.
Dr. O'Brien treated hippies at the White Bird Clinic in Eugene, Oregon in the mid-70s; served as the acting Health Officer of the Shasta County Health Department in California; and spent two years in the early 80s as an affiliate of the European Branch Headquarters of the World Health Organization in Denmark.
As the Executive Director of the nonprofit Cancer Patients Alliance (CPA) since 2001, Dr. O’Brien and his team have advocated for and supported low-income Latino community members, immigrants and farm workers with cancer in the Salinas Valley agricultural region of Monterey County, California.
Dr. O’Brien was Co-Principal Investigator of the Stanford Cancer Institute's Developmental Research Award in Translational Science, "Building an Academic-Community Partnership to Understand and Address Barriers to Cancer Care in the Salinas Valley Region of Monterey County," 2010 – 2015.
CPA has trained a number of Stanford University medical and post-doctoral students on behalf of the Valley Fellowship Program beginning in 2010 until the present.
Dr. O'Brien was a member of the Stanford / Medable team that developed the cancer aftercare app called TOGETHERCare - per NIH / NCI (SBIR 363) Phase 1 and 2 grants from 9/18/2017 until 9/30/2022.
Dr. O’Brien was on the Stanford-based research team in 2018 that piloted and studied the efficacy of the “Healthkey” behavioral health app for SAMHSA, CDC and the Council of State and Territorial Epidemiologists.
Beginning 2019, he was Co-Principal Investigator with the Stanford University group that has helped reduce cancer disparities by increasing access to the emerging DNA technologies - and facilitating cultural translation in Monterey County - pursuant to 4-year support from the California Initiative to Advance Precision Medicine.
In 2021, CPA received a 5-year grant award from the Robert Wood Johnson Foundation to further their advocacy work with the Latino community and farm workers with cancer in the Salinas Valley.
In June 2021, CPA was selected by the California GOTV medical academic consortium including the Stanford University School of Medicine as led by UCLA - to conduct the "Get Out the Vaccine to Stop Covid-19" initiative for low-income populations in Monterey County, California.
Dr. O'Brien was awarded a grant from SAMHSA through the California Department of Health Care Services (administered by Sierra Health Foundation) as the Lead for the 2024-2025 collaborative consisting of CPA, Monterey County Behavioral Health, Mujeres en Acción, and NAMI Monterey County for the "Behavioral Health Recovery, Access and Equity for Latinos" (BHRAEL) initiative.
Since 2016 Dr. O'Brien has been on the Institutional Review Board of Clinica de Salud del Valle de Salinas. He is currently a member of the Stanford Cancer Institute Community Advisory Board. Dr. O’Brien is a past editor of the Berkeley Wellness Letter, Medicine on the Net and Cancer Informatics. -
Minggui Pan, MD, PhD
Clinical Professor, Medicine - Oncology
BioDr. Pan is a board-certified, fellowship-trained medical oncologist with the Stanford Medicine Cancer Center and a clinical professor in the Department of Medicine, Division of Oncology.
He diagnoses and treats various oncological conditions and specializes in the treatment of bone and soft tissue sarcoma. He creates personalized and comprehensive care plans for each patient he serves.
Dr. Pan’s research focuses include understanding how genomic alterations impact the biological behavior and prognosis of sarcomas. In his work, he identifies new targets for developing innovative therapeutics for sarcoma treatment.
Dr. Pan has more than eighty publications and presented many abstracts in several cancer and immunology conferences. His papers have been published in the Journal of Clinical Oncology, JCO Precision Oncology, Clinical Cancer Research, Nature Review Clinical Oncology, Nature Nanotechnology, Frontier Endocrinology, JCO Oncology Practice, Journal of Hematology and Oncology, British Journal of Cancer Reports, and other peer-reviewed journals. He has also presented to his peers at international, national, and regional meetings, including the annual meetings of American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), European Society for Medical Oncology (ESMO), Chinese Society Of Clinical Oncology (CSCO), Connective Tissue Oncology Society (CTOS) and others.
Dr. Pan is a member of American Society of Clinical Oncology, American Association for Cancer Research, American Association of Immunologists, American Association for Advancement of Science, Society for Immunotherapy of Cancer, and Connective Tissue Oncology Society. Dr. Pan is also an adjunct investigator with Kaiser Permanente Division of Research. -
Divya Parikh, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Divya Parikh is board-certified in both medical oncology and internal medicine. She obtained her medical degree from Boston University School of Medicine and completed both her residency and fellowship through Stanford University. During her fellowship, she simultaneously earned a Master of Science in health policy from Stanford University.
Dr. Parikh specializes in the care of patients with genitourinary cancers. In addition to her clinical responsibilities, she currently is a clinical assistant professor of medical oncology at Stanford School of Medicine. She mentors medical residents and fellows by sharing her insights, knowledge, and expertise.
Dr. Parikh has a strong research background. She has published in multiple academic journals and presented her findings through poster and oral presentations at various medical conferences. -
Neha Patel, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Neha Patel is a triple board-certified, fellowship-trained medical oncologist with Stanford Health Care. She is also a clinical assistant professor in the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Patel provides expert, personalized care for patients with both common and rare cancers and specializes in treating patients with genitourinary cancer. She is deeply committed to delivering comprehensive, patient-centered oncology services, with an emphasis on helping individuals and their families understand their diagnosis and navigate treatment options with confidence and clarity.
Her research focuses on designing and implementing system-level interventions to advance equitable, high-value cancer care. Dr. Patel is particularly passionate about integrating oncology and palliative (symptom-relieving) care—creating collaborative models that improve patient outcomes, elevate the quality of life, and enhance the overall care experience.
Known for her compassionate and relational approach, Dr. Patel builds strong, trusting partnerships with the patients and families she serves. She prioritizes care that aligns with each individual’s values, preferences, and goals, with the aim of achieving the best possible quality of life and longevity. -
Mark Pegram
Susy Yuan-Huey Hung Professor
Current Research and Scholarly InterestsMolecular mechanisms of targeted therapy resistance in breast and other cancers
-
Harlan Pinto
Associate Professor of Medicine (Oncology), Emeritus
Current Research and Scholarly InterestsClinical Interests: general oncology, head and neck cancer Research Interests: chemoprevention trials and combined modality approaches to head and neck cancer
-
Klaus Porzig
Emeritus Adjunct Clinical Professor, Medicine - Oncology
BioKlaus Porzig is an Emeritus Adjunct Clinical Professor at Stanford. He was active in Stanford’s clinical oncology program from 1979 until 2008. He was an Attending Physician on the Oncology inpatient service (MED III initially and then MED X) annually from 1979 until retirement in 2008. He was active in the breast cancer program during those decades. Dr. Porzig was a founding partner in South Bay Oncology in 1979 which became part of the Stanford Cancer Center in the Southbay after his retirement. From 2013 to 2021, he was a member of the Stanford Mediine Alumni Association Board of Governors and served as chair of the Awards Committee during that time. Klaus has been a docent at Stanford's Jasper Ridge Biological Preserve since 2018.
PROFESSIONAL EDUCATION
B.A., Stanford University, Biology “With Great Distinction” and “Departmental Honors” (1969)
M.D., Stanford University School of Medicine (1973)
POSTGRADUATE TRAINING
Internship: Internal Medicine, University of California, San Francisco (1973-74)
Residency: Internal Medicine, Stanford (1974-75)
Research Fellowship: Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH (1976-78)
Clinical Fellowship: Medical Oncology, Stanford University (1975-76, 1978-79)
ACADEMIC HONORS AND AWARDS
Phi Beta Kappa (1968)
Alpha Omega Alpha (1972)
Winslow J. Cutting Book Award for research in Pharmacology, Stanford (1973)
Russel V. Lee Clinical Teaching Award for Excellence in Clinical Teaching, Medicine, Stanford (1994,1997,1999, and 2000)
Thomas E. Davis Award for Clinical Teaching, Oncology, Stanford (1995)
Honorary Lifetime Medical Staff, Stanford University Hospital (2013) -
Kavitha Ramchandran
Clinical Professor, Medicine - Oncology
Current Research and Scholarly InterestsMy research focuses on innovative models of care delivey to understand how to integrate primary and specialist palliative care. We also do work in palliative care education and how to scale our education to be impactful and sustainable. We are evaluating online models.
In cancer care I do research on novel therapeutics in thoracic malignancies including immunotherapy, new targeted agents, and new sequencing of approved drugs. -
Julia D. Ransohoff
Instructor, Medicine - Oncology
BioDr. Ransohoff received her B.A. from Harvard College in Human Developmental and Regenerative Biology and completed her medical training at Stanford University, where she received her M.D., completed residency in internal medicine, and fellowship training in hematology and oncology as part of the American Board of Internal Medicine Physician Scientist Training Program.
Dr. Ransohoff is a physician-scientist dedicated to improving breast cancer treatments and outcomes through developing genomic methods to profile how tumors respond to treatment. Her research focuses on molecular approaches to understand the variable clinical responses of breast cancers to treatment at the genomic level by profiling molecular residual disease. Her current work involves exploring mechanisms of chemoresistance and immune evasion and identifying novel therapeutic targets. In related work, she also studies epidemiological risk factors for breast cancer mortality with a focus on the gut microbiome, oncofertility, and racial and ethnic differences in treatment response. Dr. Ransohoff's research has been supported by the ASCO Conquer Cancer Foundation, the Terri Brodeur Breast Cancer Foundation, the Stanford Cancer Institute, ECOG-ACRIN, and the Chan Zuckerberg Initiative.
As an Instructor in the Division of Medical Oncology, Dr. Ransohoff is also a clinically active oncologist, treating patients with breast cancer. -
Fauzia Riaz, MD, MHS
Assistant Professor of Medicine (Oncology)
BioDr. Riaz is dedicated to advancing breast cancer treatment through an innovative clinical trial program that focuses on cutting-edge therapeutics and biomarkers.
Dr. Riaz is studying circulating tumor (ct)DNA-minimal residual disease (MRD) as a pivotal biomarker for early-stage breast cancer. She aims to enhance its use in surveillance and early detection while guiding personalized treatment strategies through novel clinical trials. Furthermore, she is committed to improving immunotherapy efficacy by modifying the tumor microenvironment. Her research involves developing early-phase trials that integrate novel therapeutic approaches, combining immunotherapy and radiotherapy. As a Clinical Assistant Professor at Stanford University School of Medicine, Dr. Riaz is also committed to improving the accessibility of cutting edge therapies to all patients. She is leading a collaborative effort with multiple institutions to develop databases that track patient outcomes and inform treatment practices.
Dr. Riaz’s overarching goal is to expand early-phase clinical trials and foster academic-industry partnerships to advance the field of breast oncology and improve patient care. -
Rajat Rohatgi
Professor of Biochemistry and of Medicine (Oncology)
Current Research and Scholarly Intereststhe overall goal of my laboratory is to uncover new regulatory mechanisms in signaling systems, to understand how these mechanisms are damaged in disease states, and to devise new strategies to repair their function.
-
Mohana Roy, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Roy is a medical oncologist and a clinical assistant professor in the Stanford University School of Medicine Department of Medicine, Division of Medical Oncology. She has expertise in Lung and Thoracic cancers, but with a broad clinical interest in oncology, including in Carcinoma of Unknown Primary (CUP).
Dr. Roy became an oncologist because of her passion for patient care. She is committed to being a clinician and is focused on improving the patient experience, given how the complex process of getting cancer care can be made a bit more seamless. She is the Associate Medical Director for Quality at Stanford Cancer Center from 2022.
She had led major efforts in the cancer program including starting standardized discharge follow up for patients after hospitalization, starting same day clinical care at the cancer center, and also expediting care for patients with an unclear diagnosis of cancer but with suspected imaging concerns.
Her research interests include access to clinical trials, quality improvement and improving care delivery. In that effort, she has published on work regarding patient reported outcomes (PROs), through distress screening with the Stanford Medicine Cancer Center, and in care for patient with limited English proficiency.
Dr. Roy received her medical degree from Albert Einstein College of Medicine, and then completed residency training at Beth Israel Deaconess Medical Center. She then completed fellowship training in Hematology and Oncology at Stanford, where she was chief fellow. -
Anuja Anand Sathe
Instructor, Medicine - Oncology
Current Research and Scholarly InterestsI am interested in understanding the determinants of therapeutic resistance in cancer. I investigate the composition of the tumor microenvironment and adaptive responses to therapy using single-cell and spatial approaches.
-
Lidia Schapira
Professor of Medicine (Oncology)
BioDr. Schapira is a medical oncologist with clinical expertise in the treatment of breast cancer. As the inaugural Director of Stanford's Cancer Survivorship Program, she has developed a thriving research and clinical program focused on optimizing health outcomes for people living with and beyond cancer. Dr. Schapira is interested in training future generations of physician-scientists as well as the broader community of practicing physicians through the design of innovative educational programs. Dr. Schapira's advocacy for people with cancer led to her appointment as Editor-in-Chief of the American Society of Clinical Oncology's website for the public,Cancer.Net, a position she held from 2015 until-2021. She served on the Board of Directors of the American Psychosocial Oncology Society and as Chair of the Psychosocial Interest Group of the Multinational Society for Supportive Care in Cancer. Dr. Schapira is particularily committed to reducing inequities in cancer outcomes and improve access to cancer care and cancer clinical trials. Dr. Schapira has published numerous manuscripts, lectures both nationally and internationally on issues of cancer survivorship and served as Associate Editor of the narrative section, Art of Oncology, for the Journal of Clinical Oncology from 2013 until 2023.
-
Joseph Schroers-Martin
Assistant Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMedical heme/onc focused on molecular cancer diagnostics and novel biomarkers.
-
Sumit Shah
Clinical Associate Professor, Medicine - Oncology
Clinical Associate Professor (By courtesy), UrologyBioDr. Sumit Shah specializes in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. He also serves as an investigator on numerous clinical trials, with a focus on novel immunotherapy agents. His academic interests also include digital health technologies and novel healthcare delivery services, both in the domestic and international setting. Dr. Shah graduated with distinction in biomedical engineering from Duke University, received his medical doctorate from Stanford University, and Masters in Public Health from Harvard University. He completed his internal medicine residency at the University of California, San Francisco (UCSF) where he stayed on faculty for one year before returning to Stanford for his fellowship training in medical oncology, where he now serves on the faculty.
-
Shagufta Shaheen
Clinical Assistant Professor, Medicine - Oncology
BioDr. Shaheen specializes in the gastrointestinal malignancies and she has expertise in treating neuroendocrine tumors (NETs). Following her fellowship in Hematology and Oncology, Dr Shaheen completed an advanced fellowship in Neuroendocrine tumors from Stanford University. The NET advanced fellowship is first of its kind in United State started under the leadership of Dr Pamela Kunz who is the founding Director of the Stanford Neuroendocrine Tumor Program established in 2015. After completing her advanced fellowship, Dr Shaheen joined Stanford Oncology division as Clinical Assistant Professor. Dr Shaheen is involved in further developing the neuroendocrine oncology program at Stanford which serves as a centre of excellence in the treatment of neuroendocrine tumors. Dr Shaheen is actively involved in clinical research and clinical trials. Dr Shaheen is also involved in taking care of patients admitted to the oncology service as well as resident and fellow teaching.
-
Anjali Sibley MD, MPH
Clinical Associate Professor, Medicine - Oncology
BioDr. Sibley is a Clinical Associate Professor of Medicine (Oncology) at Stanford School of Medicine. She is the Director of the Stanford Medicine Cancer Center in Emeryville and is a board-certified, fellowship-trained hematologist and medical oncologist.
Her clinical interests include treating solid tumor cancers, lung cancers, blood cancers and benign blood conditions. She is interested in cancer prevention and reducing disparities in hematologic/oncologic care among underserved populations, and successful cancer survivorship programs.
In addition to responsibilities related to patient care and overseeing the Cancer Center in Emeryville, Dr. Sibley has developed and is leading an innovative cancer survivorship clinic, including an exercise initiative. She also is passionate about advancing clinical trial enrollment for medically underserved populations and she serves on the Cancer Network’s East Bay Health Equity Committee leading lung cancer screening efforts in the East Bay. She is also working on a Stanford Cancer Institute-funded study examining psychosocial factors and cardiac health in Black cancer patients in the East Bay.
She believes that providing patient care is a true privilege. Dr. Sibley utilizes a patient-centered practice approach that addresses multiple aspects of a patient’s well-being. Her research interests have included chemoprevention of breast cancer and the development of magnetic resonance imaging technology in breast cancer detection and mapping. She has also led community-based efforts to implement low-dose computed tomography (LDCT) as a screening tool for cancer.
Dr. Sibley’s publications include articles on breast cancer prevention, breast magnetic resonance imaging, and other topics. Her work has appeared in American Journal of Hematology, JAMA, the Breast Journal, Internal Medicine News, and elsewhere. Dr. Sibley was invited to deliver a peer-reviewed presentation on community-based cancer screening and preventive education to the Global Health Council. Dr. Sibley is on the board of directors of the Cancer Support Community SF Bay Area. She has also served as a clinic physician for the Native American Health Center of Oakland, on the Committee on Health Equity of the American Public Health Association, and as chair and vice chair of the Cancer Forum Caucus of the American Public Health Association. She is a member of the American Society of Clinical Oncology, American Society of Preventive Oncology, and American Society of Hematology. She has provided volunteer services to the Global Health Council and to the Cancer Patients Aid Association, for whom she conducted a patient screening and education program in Mumbai, India. -
Branimir I. Sikic, M. D.
Professor of Medicine (Oncology), Emeritus
Current Research and Scholarly InterestsResearch Interests: cancer pharmacology, mechanisms of resistance to anticancer drugs, regulation and function of MDR1 and tubulin genes, CD47 as a target for activation of anticancer macrophases, Phase I trials of new drugs, gene expression profiling of cancers
-
Allyson Spence
Clinical Assistant Professor, Medicine - Oncology
BioAllyson Spence MD, PhD is a Clinical Assistant Professor of Medicine in the Stanford University School of Medicine. She received her MD, PhD in the MSTP program at Vanderbilt University School of Medicine, studying basic mechanisms of transcription using Saccharomyces cerevisiae as a model system in the laboratory of Dr. Tony Weil. She went on to an internship and residency at the University of Pennsylvania before returning to Stanford to complete her Oncology fellowship training. She did a postdoctoral fellowship at Stanford in the department of Molecular Biology under the auspices of Dr. Margaret Fuller, where she was the recipient of a career award.
She has transitioned from basic science research to clinical medicine where she sees patients diagnosed with breast cancer. Additionally, she has an appointment at the Palo Alto VA as a staff oncologist where she focuses on women's cancers and women at high risk of developing breast and gynecologic cancers. She is involved in several translational research projects at the VA, as well as being involved in clinical trials. -
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsClinical interests: general oncology, genito-urinary malignancy Research interests: conducting clinical trials in advanced prostate cancer, bladder cancer and renal cell carcinoma
-
Frank E. Stockdale
Maureen Lyles D'Ambrogio Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsLaboratory and clinical research in breast cancer ; Normal and abornal differentiation and growth
-
Fangdi Sun
Clinical Instructor, Medicine - Oncology
BioDr. Sun is a medical oncologist and clinical investigator at Stanford University. She specializes in the treatment of patients with head and neck malignancies, with specific interests in virus-driven malignancies and novel, biomarker-guided therapies in head and neck cancer. She received her medical degree from Harvard Medical School, followed by a residency and chief residency at the University of California, San Francisco, and then served as chief fellow in hematology and medical oncology at Stanford University. She has earned honors and recognition from the American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC), among other organizations.
-
Melinda L. Telli, M.D.
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.
-
Haluk Tezcan, MD
Adjunct Clinical Associate Professor, Medicine - Oncology
BioClinical focus:
Breast Oncology
Molecular Diagnostics
Dr. Tezcan is a medical oncologist and hematologist with over three decades of diverse experience in cancer management and research.
He is leading the clinical development of Droplet Biosciences' novel liquid biopsy technology, a first-in-class lymphatic fluid molecular residual disease assessment, overseeing the scientific and clinical development of the technology. With over three decades of direct patient care and clinical trial experience as a principal investigator and director, both in academia and private practice, he has a firsthand understanding of the unmet clinical needs of physicians and patients, as well as broad experience in clinical trial design and implementation.
He is also co-principal at Athea Oncology, guiding practices and hospitals in developing clinical trial programs and high-value real-world data collection and diagnostic companies in clinical development. He is also a reviewer of JCO Precision Medicine.
Before joining Athea Oncology and Droplet Biosciences, he was the co-founder of LexentBio, which was successfully acquired by Roche/FMI. He also served as Director of Translational Medicine at Genomic Health and as Vice President, leading oncology development at Counsyl, where he integrated science with clinical product development. He established the CA.RE.foundation, a cancer research foundation dedicated to enabling the execution of clinical trials across community oncology sites throughout the Northwest US. He has independently built multiple software tools to help oncologists navigate the practical realities of their daily work. -
Heather Wakelee
Winston Chen and Phyllis Huang Professor
Current Research and Scholarly InterestsDr. Wakelee's research is focused on clinical trials and translational efforts in patients with lung cancer and other thoracic malignancies such as thymoma and thymic carcinoma. Other interests include translation projects in thoracic malignancies and collaborations with population scientists regarding lung cancer questions.
-
Maggie Zhou
Instructor, Medicine - Oncology
BioDr. Zhou is an Instructor in the Division of Oncology at Stanford University with an academic focus in sarcoma. She graduated from Yale University with a B.A. and double majored in economics and molecular, cellular, and developmental biology. She subsequently received her M.D. from Stanford University School of Medicine, where she completed her internal medicine residency and fellowship training.
Her research interests center around the development of novel therapeutics, understanding pathophysiology of rare sarcoma subtypes, and evaluating the utility of circulating tumor DNA for assessing disease response and detecting minimal residual disease. She has co-authored over 20 peer-reviewed publications, including in Clinical Cancer Research and Nature Cell, and is an active member of the Sarcoma Clinical Trial Working Group in the Hoosier Cancer Research Network. Her research has been supported by the Chinese American Hematologist and Oncologist Network and Sarcoma Alliance for Research through Collaboration.
